Capital World Investors
ABCL icon

Capital World Investors’s AbCellera Biologics ABCL Stock Holding History

Capital World Investors’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107M Buy
13,588,349
+227,253
+2% +$1.11M 0.01% 399
2026
Q1 		$46.6M Hold
13,361,096
– – 0.01% 464
2025
Q4 		$45.7M Hold
13,361,096
– – 0.01% 424
2025
Q3 		$67.2M Hold
13,361,096
– – 0.01% 381
2025
Q2 		$45.8M Hold
13,361,096
– – 0.01% 418
2025
Q1 		$29.8M Buy
13,361,096
+5,427,483
+68% +$15.6M ﹤0.01% 443
2024
Q4 		$23.2M Buy
+7,933,613
New +$22.1M ﹤0.01% 452
2024
Q3 		– Sell
-5,318,793
Closed -$15.7M – 535
2024
Q2 		$15.7M Sell
5,318,793
-3,032,500
-36% -$11.5M ﹤0.01% 455
2024
Q1 		$37.8M Hold
8,351,293
– – 0.01% 415
2023
Q4 		$47.7M Sell
8,351,293
-69,200
-0.8% -$321K 0.01% 389
2023
Q3 		$38.7M Hold
8,420,493
– – 0.01% 399
2023
Q2 		$54.4M Sell
8,420,493
-907,000
-10% -$6.19M 0.01% 367
2023
Q1 		$70.3M Hold
9,327,493
– – 0.01% 356
2022
Q4 		$94.5M Sell
9,327,493
-253,266
-3% -$2.93M 0.02% 340
2022
Q3 		$94.8M Sell
9,580,759
-3,457,598
-27% -$37.9M 0.02% 339
2022
Q2 		$139M Sell
13,038,357
-5,229,418
-29% -$44.3M 0.03% 306
2022
Q1 		$178M Sell
18,267,775
-3,783,928
-17% -$35.8M 0.03% 310
2021
Q4 		$315M Buy
22,051,703
+2,230,296
+11% +$33.8M 0.05% 267
2021
Q3 		$397M Buy
19,821,407
+6,405,970
+48% +$113M 0.07% 235
2021
Q2 		$295M Buy
13,415,437
+9,254,567
+222% +$255M 0.05% 267
2021
Q1 		$141M Buy
4,160,870
+521,447
+14% +$20.8M 0.03% 332
2020
Q4 		$146M Buy
+3,639,423
New +$166M 0.03% 310

Other funds holding ABCL

TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Capital World Investors's ABCL Position: Q2 2026 in Review

Capital World Investors increased its AbCellera Biologics (ABCL) stake by 1.7% in Q2 2026, buying an estimated $1.11M and bringing the position to 13,588,349 shares worth $107M. The position accounts for 0.01% of the portfolio, ranked #399.

Capital World Investors first reported a position in ABCL in Q4 2020 and has held it in 22 quarters since. The position peaked at $397M in Q3 2021. 109 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Capital World Investors held 13,588,349 shares of AbCellera Biologics worth $107M as of Q2 2026.
  • Capital World Investors bought 227,253 AbCellera Biologics shares in Q2 2026, an estimated $1.11M.
  • AbCellera Biologics made up 0.01% of Capital World Investors's portfolio in Q2 2026, its #399 holding.
  • Capital World Investors first reported a position in AbCellera Biologics in Q4 2020 and has held it in 22 quarters since.
  • Capital World Investors's AbCellera Biologics position peaked at $397M in Q3 2021.
  • 109 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Capital World Investors's 13F filing for Q2 2026, filed 12 Aug 2026.